The Anticoagulation Quality Improvement Analyzer (AQuIA) is a VeriSign Code Signing Certificate software to identify gaps in care between recognized anticoagulation guidelines and practice patterns in a health-system based on retrospective pharmacy and medical claims analysis. Benchmark data from nationally representative commercial, Medicare and Medicaid referenced datasets are displayed alongside plan specific data as a means to quickly compare plan demographics, anticoagulation therapy, and resource utilization. In addition to customized population level data, this analyzer has the functionality to provide patient and provider level measures to identify opportunities to develop interventions that promote quality improvement, increased treatment of at risk patients, and potentially decrease health care resource utilization. The user-friendly interface will also provide additional descriptive and actionable measures at the patient, provider and health-plan levels that are potentially meaningful to pharmacy, medical and quality improvement directors.

The Anticoagulation Quality Improvement Analyzer (AQuIA) Atrial Fibrillation (AFib) Integrated Module is a Symantec Code Signing Certificate software to identify gaps in care between recognized anticoagulation guidelines and practice patterns in a population. The tool is designed to conduct retrospective analyses of claims (medical and pharmacy) and/or electronic health record (EHR) data. The purpose of the tool is to assist your organization’s evaluation of current practice patterns, resource utilization, and quality measure attainment overtime. In addition to customized population level data, this analyzer has the functionality to provide patient and provider level measures to identify opportunities to develop interventions that promote quality improvement, increased treatment of at risk patients, and potentially decrease health care resource utilization. The user-friendly interface will also provide additional descriptive and actionable measures at the patient, provider and organization levels that are potentially meaningful to pharmacy, medical and quality improvement directors.

(Please use Chrome browser to access this content. Other browsers may not be supported.)

The Shared Decision-Making (SDM) Tool for Oral Anticoagulant Medications in Nonvalvular Atrial Fibrillation patients is a decision-aid tool intended to improve patient-provider communication and decision making about oral anticoagulation therapy for nonvalvular atrial fibrillation (A Fib). The SDM Tool educates patients about NVAF and the risks and benefits of oral anticoagulant therapy (with warfarin used as the reference drug), and helps patients evaluate and take into account their concerns and preferences in choosing therapy. The SDM Tool further provides risk calculators to help clinicians assess and communicate to their patients their risks of stroke and major bleeding, with and without anticoagulant therapy, via easy-to-understand graphics, while addressing their patients’ concerns about oral anticoagulant therapy via a guided discussion on patient preferences.  

As healthcare becomes more patient-centered, there is a growing need for SDM tools to help patients engage in their own treatment decision in partnership with their healthcare providers. This tool is designed to promote patient-centered care and facilitate interactions between patients and their healthcare providers in order to promote shared decision making. 

The Quality Population Analyzer Tool for Health systems (QualityPATH) is a Symantec Code Signing Certificate software that allows your organization to review type 2 diabetes (T2DM) data from a quality metrics perspective based on retrospective medication, medical, and/or laboratory data analysis. QualityPATH can process claims (medical and pharmacy) and/or electronic health record (EHR) data. Reference data from an integrated claims-EHR database are displayed alongside your organization’s data as a means to quickly compare demographics, antihyperglycemic agent utilization, resource utilization, and adherence to quality measures. In addition to providing customized population-level data, the analyzer has the functionality to provide patient- and provider-level reports.

The Assessment for Quality Improvement and Risk Evaluation program assists customers in identifying opportunities to improve treatment for patients with schizophrenia. Using actual client data, this tool provides a quick look into adherence rates, hospitalizations, and likelihood of future non-adherence and hospitalizations.

More information on the Assessment for Quality Improvement and Risk Evaluation (QI-RE) Tool [PDF] and QI-RE Data Preparation Guide [PDF].

The Autism Behavior Inventory (ABI), is a 73 item caregiver report developed for assessing changes in core and associated symptoms of autism spectrum disorder (ASD). It is designed to capture the behavior of individuals with ASD, aged three to adult, that have occurred over the past week. It is a web or paper based tool which assesses behavior across five domains (two ASD core domains: social communication, restrictive and repetitive behaviors; three associated domains: mental health, self-regulation, and challenging behavior). The paper version of the ABI is available for download and use, subject to conditions.

The Schizophrenia Health Outcomes Research Tutorial Tool (SHORTT) is a web-based eLearning application developed to enhance your understanding of clinical research in schizophrenia and to provide important points to consider when interpreting study design, endpoints, and methodologies. This application provides a didactic overview of three chapters: Chapter 1 discusses study design in schizophrenia; Chapter 2 discusses common endpoints used in clinical studies of schizophrenia; and lastly Chapter 3  discusses some methodological considerations in clinical studies. The module concludes with a checklist, which can be used as a reference while evaluating published clinical studies.

The schizophrenia Treatment and Assessment Reporting Tool (START) is a documentation and reporting tool for healthcare professionals (HCPs) who treat patients with schizophrenia. This local-server based application collects retrospective data on clinical, economic, and other patient reported outcomes up to 12-months before and after the initiation of an atypical long-acting antipsychotic therapy.  START allows population-level reporting and further generates aggregated reports that HCPs could potentially use in response to local reimbursement or formulary reviews. START may be used by HCPs providing outpatient follow-up care across variety of clinical settings, e.g. private clinical practices, community mental health centers, interconnected systems, or other outpatient treatment facilities to patients suffering from schizophrenia.

Additional information on the Schizophrenia Treatment and Assessment Reporting Tool (START) can be downloaded here.